The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias
Abstract
The chemokine receptor CXCR4 mediates the migration of hematopoietic cells to the stroma-derived factor 1α (SDF-1α)–producing bone marrow microenvironment. Using peptide-based CXCR4 inhibitors derived from the chemokine viral macrophage inflammatory protein II, we tested the hypothesis that the inhibition of CXCR4 increases sensitivity to chemotherapy by interfering with stromal/leukemia cell interactions. First, leukemic cells expressing varying amounts of surface CXCR4 were examined for their chemotactic response to SDF-1α or stromal cells, alone or in the presence of different CXCR4 inhibitors. Results showed that the polypeptide RCP168 had the strongest antagonistic effect on the SDF-1α– or stromal cell–induced chemotaxis of leukemic cells. Furthermore, RCP168 blocked the binding of anti-CXCR4 monoclonal antibody 12G5 to surface CXCR4 in a concentration-dependent manner and inhibited SDF-1α–induced AKT and extracellular signal-regulated kinase phosphorylation. Finally, RCP168 significantly enhanced chemotherapy-induced apoptosis in stroma-cocultured Jurkat, primary chronic lymphocytic leukemia, and in a subset of acute myelogenous leukemia cells harboring Flt3 mutation. Equivalent results were obtained with the small-molecule CXCR4 inhibitor AMD3465. Our data therefore suggest that the SDF-1α/CXCR4 interaction contributes to the resistance of leukemia cells to chemotherapy-induced apoptosis. Disruption of these interactions by the peptide CXCR4 inhibitor RCP168 represents a novel strategy for targeting leukemic cells within the bone marrow microenvironment. [Mol Cancer Ther 2006;5(12):3113–21]
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cellular survival: a play in three Akts
Datta, S. R., Brunet, A., & Greenberg, M. E. (1999) · Genes & Development · doi:10.1101/gad.13.22.2905 · Cited by 4,216
A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1)
Bleul, C. C., Fuhlbrigge, R. C., Casasnovas, J. M., Aiuti, A., & Springer, T. A. (1996) · The Journal of experimental medicine · doi:10.1084/jem.184.3.1101 · Cited by 1,482
Cited by
Klopp, A. H., Gupta, A., Spaeth, E., Andreeff, M., & Marini, F. (2011) · Stem Cells · doi:10.1002/stem.559 · Cited by 562
Self-citationThe Bone Marrow Microenvironment as a Tumor Sanctuary and Contributor to Drug Resistance
Meads, M. B., Hazlehurst, L. A., & Dalton, W. S. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-2223 · Cited by 520
CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers
Burger, J. A., & Peled, A. (2009) · Leukemia · doi:10.1038/leu.2008.299 · Cited by 462
A role for cancer stem cells in therapy resistance: Cellular and molecular mechanisms
Cojoc, M., Mäbert, K., Muders, M. H., & Dubrovska, A. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2014.06.004 · Cited by 393
Burger, J. A., Quiroga, M. P., Hartmann, E., Bürkle, A., Wierda, W. G., Keating, M. J., & Rosenwald, A. (2009) · Blood · doi:10.1182/blood-2008-07-170415 · Cited by 330
Metadata
- Authors
- Zeng, Z., Samudio, I. J., Munsell, M., An, J., Huang, Z., Estey, E., Andreeff, M., & Konopleva, M.
- Venue
- Molecular Cancer Therapeutics
- Published
- 2006-12-01
- Volume
- 5
- Issue
- 12
- Pages
- 3113-3121
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- OpenAlex
- W2128828794
- Cited by
- 184
- References
- 2
- FWCI
- 5.58
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias. https://app.cochat.ai/papers/10.1158/1535-7163.mct-06-0228
- The paper
- Zeng, Z., Samudio, I. J., Munsell, M., An, J., Huang, Z., Estey, E., Andreeff, M., & Konopleva, M. (2006). Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-06-0228
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.